Conference reports

Preconception safety signal with dolutegravir: data from the Tsepamo study

What to watch: HIV cure-related research at AIDS 2018

AIDS 2018: Programme online and late-breaker highlights announced three weeks before the conference

19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore

Unbound dolutegravir plasma concentrations unchanged in pregnancy and standard dosing crosses the placenta in placental perfusion model

Etravirine dispersible paediatric tablet has greater bioavailability when dispersed in water compared to swallowed whole  

Reduced exposure to elvitegravir in pregnancy: results from the PANNA Network  

Rifabutin dosed 2.5 mg/kg daily with lopinavir/r in children achieves comparable exposure to adults 

No clinically relevant reduction in oral cabotegravir when co-administered with rifabutin  

Boosted darunavir 800/100 mg twice daily might overcome interaction with rifampicin

Efavirenz side effects and other drug-drug interactions are common in Ugandan cohort

19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore

Dolutegravir 50 mg twice daily sufficient with rifampicin but levels reduced significantly with 100 mg once daily 

Vaginal ring reduces efavirenz but not atazanavir exposures 

Dispersible paediatric versions of dolutegravir provide higher bioavailability than immediate release formulations  

Fourth Joint Conference of BHIVA/BASHH (4th BHIVA/BASHH)

Low PEP and PrEP awareness among trans people in London and their partners

Low awareness of PrEP in BME communities in Leeds but high interest in use

Younger people living with HIV more likely to have a positive self image

Zero or negligible risks of HIV, HBV or HCV transmission by biting or spitting

UK-CAB community representation on guideline panels and research studies

Fourth Joint Conference of BHIVA/BASHH (4th BHIVA/BASHH)

Almost 1 in 8 people with symptoms turned away from sexual health clinics in SE London: 40% are under 25 and 6% under 18 years old

A new framework for best HIV care: BHIVA Standards of Care revised and updated (2018)

Key changes to upcoming UK HIV pregnancy guidelines (2018)

Pregnancy studies at 4th Joint BHIVA/BASHH Conference

Meta-analysis of TAF vs TDF in boosted vs unboosted regimens

Meta-analysis of dolutegravir in naive, experienced and switch studies

Not claptrap: kissing as the strongest route for oral gonorrhoea

Rapid PrEP uptake in Scotland exceeds expectations

Drug cost savings from routine use of generic ARVs: safety and efficacy in practice

CROI 2018: third reports

No increased risk of IRIS in people with low CD4 counts receiving raltegravir in the REALITY trial

Isoniazid preventive TB therapy in pregnancy and postpartum: recommendations now need to be re-evaluated

Efavirenz might decrease effectiveness of the vaginal contraceptive ring

Switch to TAF appears safe and effective in adolescents: similar PK to adults

Doubling raltegravir dose could overcome interaction with rifampicin in children aged 2 to 6

Twice-daily bictegravir does not overcome drug interaction with rifampicin

Reducing risk of myocardial infarction (MI) in HIV positive people

M184V mutation associated with increased risk of viral blip but not viral failure with 3TC-based dual therapy

CROI 2018: second reports

Ibalizumab 24-week phase 3 results and susceptibility to drug-resistant HIV

Statin use might reduce risk of cancer in HIV positive people

Rate of bone loss on ART slows after the first year

Standard dose of dolutegravir sufficient in late pregnancy: interim results from DolPHIN1 study

Women’s risk of becoming HIV positive increases three-fold in late pregnancy and four-fold postpartum

Cure research at CROI 2018: defining and reducing the reservoir and the risks from interrupting treatment

25th Conference on Retroviruses and Opportunistic Infections (CROI 2018)

Inching towards an HIV cure: bNAb and TLR-7 agonist reduce viral rebound off-ART in macaques

No HIV evolution in plasma or lymph nodes on suppressive ART and no impact from further intensification

Dual therapy can reduce TB prophylaxis from nine months to one: fewer side effects and more people complete treatment

Twice-daily dolutegravir is effective and tolerable with rifampicin 

Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin

Efavirenz 400 mg can be given with anti-tuberculosis treatment 

Bictegravir at CROI 2018: switching studies and drug resistance analyses

PrEP at CROI 2018 (part 1): Access in Australia and the US

PrEP at CROI 2018 (part 2): Animal studies for future drugs

BHIVA best of CROI feedback workshops

CROI 2018 – highlights from the preliminary programme

16th European AIDS Conference (EACS 2017)

Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results

D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets

Dolutegravir-based dual therapy as switch option in multiple studies

Switch study shows F/TAF non-inferior to continuing abacavir/3TC

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

Post navigation